Registry Study of Neoadjuvant Chemoradiation & Transplant for Cholangiocarcinoma Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT00301379
Recruitment Status : Recruiting
First Posted : March 10, 2006
Last Update Posted : March 26, 2018
Information provided by (Responsible Party):
Washington University School of Medicine

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : June 30, 2018
  Estimated Study Completion Date : June 30, 2020
Tsavaris, Inv New Drugs, 22:193, 2004;Verdarame, Anti-Cancer Drugs, 11:707,2000.
Picus, Proc ASCO, 13:208, 1994.
Valle JW WH, Palmer DD, Cunningham D, Anthoney DA, Maraveyas A, Hughes SK, Roughton JA, Bridgewater JA: Gemcitabine with or without cisplatin in patients (pts) with advanced or metastatic biliary tract cancer (ABC): Results of a multicenter, randomized phase III trial (the UK ABC-02 trial). J Clin Oncol 27:15s, 2009 (suppl, abstr 4503), 2009